Updates in Head and Neck Cancer Treatment: Integrating Checkpoint Inhibitor Therapy to Improve Outcomes
Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.Source: ReachMD
Camrelizumab vs Placebo in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
In this phase III trial of first-line camrelizumab/gemcitabine/cisplatin versus gemcitabine/cisplatin in patients with metastatic or recurrent nasopharyngeal carcinoma, patients received four to six cycles of therapy followed by maintenance camrelizumab or placebo. The addition of camrelizumab significantly improved progression-free survival but caused higher rates of myelosuppression.Source: Practice Update
Barbara Burtness, MD on the Efficacy of Checkpoint Inhibitors in Head and Neck Cancer.
An unanswered question in the treatment of patients with head and neck cancer, specifically those with human papillomavirus (HPV)–associated oropharynx cancer and Epstein-Barr virus–associated nasopharynx cancer, is how immune checkpoint inhibitors fit into the management of curable-stage disease, Burtness says.Source: OncLive
Weekly Paclitaxel, Carboplatin, and Cetuximab as Induction Therapy for Metastatic or Relapsed Head and Neck Cancer
Dr. Burtness: Our group at Yale undertook a retrospective analysis to look at a regimen of weekly carboplatin, paclitaxel and cetuximab, which has been studied both in ECOG and MD Anderson, and is I think pretty commonly used in practice but has not been included as a control or an experimental arm in any of the large randomized trials, which have changed practice in head and neck cancer in recent years. One of the reasons that this regimen is appealing is it's more tolerable to people with renal injury, frailty, or advanced age. And we were interested in seeing what we could learn about its activity and tolerability in the patients we had treated at Yale, including those who were elderly or frail.Source: Practice Update
Outcomes for Patients With Locally Advanced Head and Neck Cancer Receiving Neoadjuvant Pembrolizumab
One of the interesting questions that can be posed when you look at this trial design is what is the advantage of giving neoadjuvant pembrolizumab in a group of patients where you know that you're going to be taking the patient to surgery.Source: Practice Update
Head and Neck Cancer: Five Things You Need to Know
April is Head and Neck Cancer Awareness Month. Barbara Burtness, MD, Professor of Medicine (Medical Oncology) and the Disease Aligned Research Team Leader of the Head and Neck Cancers program at Yale Cancer Center, said it’s a good time to highlight warning signs, screening and prevention for this potentially deadly disease.
HPV Is the Most Common STI in the US—but Does It Go Away on Its Own? Here's How Doctors Explain It
HPV (human papillomavirus) is the most common sexually transmitted infection in the United States, according to the Centers for Disease Control and Prevention (CDC). How common? More than 79 million people have it right now. And experts estimate that about 14 million people get infected every year.Source: Parade
In Memoriam: Clarence T. Sasaki, MD 1941-2021
Clarence T. Sasaki MD, Charles W. Ohse Professor Emeritus of Surgery at the Yale School of Medicine, died peacefully on February 4, 2021. His prominent career is distinguished by his life-long passion for the academic mission, and as a champion of surgical leadership at Yale. He was the longest serving Chief of Otolaryngology, serving more than 30 years, between 1981 and 2012.
Deintensification of Treatment in HPV-Associated Cancers Holds Promise, But With Caveats
De-escalating therapy has the potential to dramatically reshape the treatment of patients with HPV-associated oropharyngeal cancers, but only if a number of key trials come back with positive long-term data.Source: Targeted Oncology
Telemedicine Best Practices
According to Douglas M. Hildrew, MD, Chair of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Telemedicine Committee and Assistant Professor of Surgery at the Yale School of Medicine, Division of Otolaryngology–Head & Neck Surgery, “On a very basic level, telemedicine involves using electronic communication strategies to provide clinical services and/or patient care remotely.Source: ENT health